The first group (22% of those analyzed) is characterized by hypermethylation of CIMP or MLH1 and, together with the related EBV subtype (9% of analyzed neoplasms) by the greatest benefit from immunotherapy. The gene discussed is MLH1; the disease is neoplasm.